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BBMT MANUSCRIPT SUBMISSION
RATE CONTINUES ACCELERATION
The pace of manuscript submis-
sions to Biology of Blood and Marrow
Transplantation continues to in-
crease—from eight or nine manu-
scripts per month in 2002 to more
than 20 manuscripts per month now.
The submission rates for the past
several years have been:
● 2002: 8.6 manuscripts per month
● 2003: 11.8 manuscripts per month
● 2004: 13.6 manuscripts per month
● 2005 to date: 20.4 manuscripts
per month
The manuscript acceptance rate
this past year was 56%.
REGISTER ONLINE FOR BMT
TANDEM MEETINGS IN HAWAII
Online registration and housing
reservations are open for the 2006
BMT Tandem Meetings that will be
held Feb. 16–20 in Honolulu.
On a single Web page at www.
asbmt.org, registrants can navigate to
meeting registration, housing reserva-
tions, preliminary program, travel dis-
counts and local tours.
Information also is provided that
compares the cost of travel and lodg-
ing for Hawaii versus other conven-
tion locations.
40 TRAVEL GRANTS AVAILABLE
FOR BMT TANDEM MEETINGS
Forty travel grants of $1,000 each
will be awarded to young investiga-
tors (not more than 5 years in the
BMT field) submitting abstracts to the
BMT Tandem Meetings.
Sessions have been designated for
oral presentation of about 60 ab-
stracts, chosen according to scores
awarded by the Abstract Review
Committees. All young investigators
who are selected to give oral presen-
tations will be awarded a travel grant.
Application for a travel grant is auto-
matic when young investigators sub-
mit abstracts.
RESEARCH AWARDS OFFERED
FOR NEW INVESTIGATORS
ASBMT has introduced two new in-
vestigator awards—one in coopera-
tion with Protein Design Labs and the
other with Astellas Pharma US.
Both awards are for $25,000 per
year, renewable for a second year.
The deadline is Dec. 1.
An award application is available
for download from the ASBMT Web
site, www.asbmt.org. Submit just the
single application to be considered
for both awards.
Protein Design Labs, Inc., acquired
ESP Pharma, Inc., in January. Astellas
was formed in April by the merger of
Fujisawa Pharmaceutical Co. and Ya-
manouchi Pharmaceutical Co.
ASBMT AND AST LAUNCH JOINT
CLINICAL RESEARCH AWARD
ASBMT and the American Society of
Transplantation (AST) have an-
nounced a joint Clinical Research
Award for new investigators.
The award is a two-year clinical re-
search grant, in the total amount of
$80,000, paid in quarterly installments
to the recipient’s institution. The dead-
line for applications is Dec. 2.
The purpose of this grant is to fund
research in areas that are of mutual
interest to both societies, including
histocompatability, immunogenetics,
stem cell research, and stem cell re-
search for tolerance induction. The
grant is intended for individuals initi-
ating their careers in solid organ or
blood and marrow transplantation.
Information, eligibility requirements
and online application are on the AST
Web site www.cmeplanning.com/
ast/event/category/2. Select “AST/
ASBMT Fellowship Grant.”
FREE ASBMT MEMBERSHIP
FOR FELLOWS IN TRAINING
Post-doctoral fellows and physi-
cians-in-training for blood and mar-
row transplantation are eligible for
free ASBMT membership.
The annual dues of $75 are waived
for new fellows-in-training in North
America who join the Society. The
program to recruit and waive the
dues of in-training members is sup-
ported by an educational grant from
ESP Pharma, a wholly owned subsid-
iary of Protein Design Labs.
Included in ASBMT membership is
a subscription to Biology of Blood
and Marrow Transplantation, and
the bulletin, Blood and Marrow
Transplantation Reviews. Among
other membership benefits are re-
duced member-rate registration at
the BMT Tandem Meetings and ac-
cess to new investigator awards and
travel grants.
Membership applications are avail-
able from the ASBMT Executive Office
or by download from the ASBMT Web
Site at www.asbmt.org. Click “Mem-
bership Application” on the home
page.
CONSORTIUM TO ADDRESS CELL
PRODUCT CODING AND LABELING
Improvements in coding and label-
ing of cellular therapy products is the
objective of a newly created consor-
tium that includes ASBMT and 10
other national and international cell
therapy organizations.
Meeting for the first time in Sep-
tember in Athens, the Cellular Ther-
apy Coding and Labeling Advisory
Group will promote standardization
of terminology and product naming.
Specifically, the Advisory Group will
review existing labeling regulations,
such as those of the FDA and the
European Tissue and Cells Directive,
and design product label templates
940
that satisfy the regulatory require-
ments.
The Advisory Group will promote
the adoption of the ISBT 128 stan-
dard in cellular therapy facilities
around the world, and provide ad-
vice and support to facilities introduc-
ing the standard. It also will be advis-
ing on the further development of
the ISBT 128 standard to support new
therapies.
The ISBT 128 standard originated
in 1994 and is being used in at least
28 countries on five continents. It
provides for a donation numbering
system that has a globally unique
identification for each cellular prod-
uct, a bar coding system for transfer
of the information on the product
label, a standard layout for the
product label and a standard refer-
ence for use in electronic communi-
cations.
Other organizations participating
in the Advisory Group are:
● AABB
● European Group on Blood and
Marrow Transplantation
● Foundation for the Accreditation
of Cellular Therapy
● International Council for Com-
monality in Blood Banking Auto-
mation, Inc.
● International Society of Blood
Transfusion
● International Society for Cellular
Therapy
● ISCT Europe
● JACIE (Joint Accreditation Commit-
tee ISCT-EBMT)
● National Marrow Donor Program
● World Marrow Donor Association
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